Lakefront Biotherapeutics (LKFT) Gross Profit (2021 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Gross Profit for 6 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Profit fell 96.94% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 468.89% YoY), while the FY2025 annual figure was $1.3 billion, up 389.73% from the prior year.
• Gross Profit retreated to $2.0 million in Q1 2026 per LKFT's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Gross Profit topped out at $1.0 billion in Q4 2025 and bottomed at -$54.5 million in Q2 2024.
• Historically, Gross Profit has averaged $116.5 million across 5 years, with a median of $60.8 million in 2023.
• Annual changes were most pronounced in 2024 — Gross Profit tumbled 189.74% — and 2025, when it soared 9908.05%.
• Lakefront Biotherapeutics' Gross Profit stood at $180.2 million in 2022, then sank by 43.69% to $101.5 million in 2023, then tumbled by 89.68% to $10.5 million in 2024, then jumped by 9908.05% to $1.0 billion in 2025, then tumbled by 99.81% to $2.0 million in 2026.
• Business Quant data shows LKFT's Gross Profit at $2.0 million in Q1 2026, $1.0 billion in Q4 2025, and $70.4 million in Q3 2025.